Functionalized Scaffold and Barrier Membrane with Anti-BMP-2 Monoclonal Antibodies for Alveolar Ridge Preservation in a Canine Model

Table 1

Remaining bone width at 1, 2, 3, and 5 mm relative to the adjacent crestal bone.

Treatment group	Remaining bone width (mm, ) at four test sites
	1 mm	2 mm	3 mm	5 mm
Anti-BMP-2 mAb			^†
Isotype matched control mAb

For anti-BMP-2-treated sites vs. control sites: and ^†. Anti-BMP-2 mAb: anti-bone morphogenetic protein 2 monoclonal antibody; SD: standard deviation.